Pneumococcal conjugate second or third-dose vaccines (PCVc) in Nepal
Nepal: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 94.0% in 2025. ◆ Volatile
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Nepal, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for pneumococcal conjugate second or third-dose vaccines (pcvc) in Nepal is 94.0%, measured in 2025.
Compared with earlier readings it is down 2.1% on the previous year and up 1,780.0% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Nepal peaked at 96.0% in 2024 and was at its lowest, 0.0%, in 2008.
Nepal ranks 46th of 194 countries on this measure, in the top quarter.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Nepal, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 0.0% | — |
| 2014 | 0.0% | — |
| 2015 | 5.0% | — |
| 2016 | 46.0% | +820.0% |
| 2017 | 80.0% | +73.9% |
| 2018 | 82.0% | +2.5% |
| 2019 | 83.0% | +1.2% |
| 2020 | 80.0% | -3.6% |
| 2021 | 84.0% | +5.0% |
| 2022 | 83.0% | -1.2% |
| 2023 | 88.0% | +6.0% |
| 2024 | 96.0% | +9.1% |
| 2025 | 94.0% | -2.1% |
Nepal compared with similar countries
- Nepal's 94.0% is above the median for lower middle income countries, which is 84.0%, 1.1× the median. (47 countries reporting)
- Nepal's 94.0% is above the median for South Asia, which is 94.0%, 1.0× the median. (6 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 29.6% | 0.0% | 83.0% | 10 |
| 2020s | 87.5% | 80.0% | 96.0% | 6 |
Countries ranked near Nepal
More health data for Nepal
- Un projection of annual infant deaths, annual growth rate -1.95 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.8518 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,326 deaths per 1,000 people (2090)
- Number of infants who die before age 1 955 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 3 (2025)
- Population ages 00-04, female, annual growth rate -1.17 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0451 units per person (2025)
- Population ages 00-04, male, annual growth rate -2.11 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Nepal?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Nepal was 94.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Nepal?
- The highest recorded value was 96.0% in 2024.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Nepal?
- The lowest recorded value was 0.0% in 2008.
- How does Nepal rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Nepal ranks 46th out of 194 countries with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Nepal?
- Over the last ten years it is up 1,780.0%. The long-run trend across the full record is volatile.
- Where does this Nepal data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).